Loading ...PCR COVID TEST ( March 2020—Dec 31 2021) …RIP
CDC Drops the RT-PCR Test as It Doesn’t Differentiate COVID-19 & Influenzas
We have been aware of this for a while but this is a New Piece from Trial Site
$5 a month subscription required. Well Worth it . But I’m posting this in the comments section
https://trialsitenews.com/cdc-drops-the-rt-pcr-test-as-it-doesnt-differentiate-covid-19-influenzas/
This seems like a pretty big deal give the WHOLE Covid SCAM was predicated upon the results from this Test which was hastily “approved” almost immediately after the “Pandemic” was “Declared”
Now it has been admitted by the “Authorities” that these tests
1…were virtually ALL false positives above 30 Cycle Threshold ( They used 40 plus)
2…do not differentiate between the flu and covid
3…continue to spit out false positives up to 12 weeks after infection
4….not yet admitted but we know that the virus has never been isolated and therefor a test is not possible
5…not yet admitted but the Nobel Prize winning Inventor of PCR ( Keri Mullis ( deceased) ) stated clearly his test cannot detect a pathogen nor equate said pathogen with a “disease”
6…In other words the tests were complete BULLSHIT and so is the “Pandemic”
So…this is a pretty big deal that they have been withdrawn .
One wonders what the replacements will be. It seems like the CDC and FDA are leaving it up to each individual lab to chose an alternative test…WTF ?
The U.S. Centers for Disease Control and Prevention (CDC) after December 31, 2021, will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. The CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives. As it turns out, the CDC now acknowledges challenges with the PCR test for testing both for COVID-19 and influenza. The CDC seeks to make a combined test that could be used as an assay for influenza and SARS-CoV-2.
After December 31, 2021, the CDC will withdraw the emergency use authorization of the PCR test for COVID-19 testing. The CDC finally admitted the test does not differentiate between the flu and COVID virus.
The FDA shares more on its website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page
.https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data?ACSTrackingID=USCDC_2146-DM61940&ACSTrackingLabel=Lab%20Alert%3A%20Changes%20to%20CDC%20RT-PCR%20for%20SARS-CoV-2%20Testing&deliveryName=USCDC_2146-DM61940
In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.
Subscribe to the Trialsitenews “COVID-19” Chann